

Edgar Filing: LYNX THERAPEUTICS INC - Form SC 13G

LYNX THERAPEUTICS INC
Form SC 13G
April 30, 2002

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G
Rule 13d-102

Under the Securities Exchange Act of 1934
(Amendment No.) (1)

Lynx Therapeutics, Inc

(Name of Issuer)

Common Stock, \$.01 Par Value

(Title of Class of Securities)

551812308

(CUSIP Number)

April 26, 2002

(Date of Event which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which
this Schedule is filed:

- Rule 13d-1 (b)
 Rule 13d-1 (c)
 Rule 13d-1 (d)

(1) The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934 ("Act") or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see
the Notes).

CUSIP No. 551812308

13G

Page 2 of 5

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Joseph Edelman

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)
(b)

3 SEC USE ONLY

Edgar Filing: LYNX THERAPEUTICS INC - Form SC 13G

4 CITIZENSHIP OR PLACE OF ORGANIZATION

United States

5 SOLE VOTING POWER
2,700,000 (includes 1,940,000 shares of common stock, par
value \$0.01 per share and warrants to purchase 760,000
shares of common stock, par value \$0.01 per share)

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH

6 SHARED VOTING POWER

0

7 SOLE DISPOSITIVE POWER
2,700,000 (includes 1,940,000 shares of common stock, par
value \$0.01 per share and warrants to purchase 760,000
shares of common stock, par value \$0.01 per share)

8 SHARED DISPOSITIVE POWER

0

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2,700,000 (includes 1,940,000 shares of common stock, par value \$0.01 per share
and warrants to purchase 760,000 shares of common stock, par value \$0.01 per
share)

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

9.26%

12 TYPE OF REPORTING PERSON*

CUSIP No. 551812308

13G

Page 3 of 5

Item 1(a). Name of Issuer:

Lynx Therapeutics, Inc.

Item 1(b). Address of Issuer's Principal Executive Offices:

25861 Industrial Blvd.
Hayward, California 94545

Item 2(a). Name of Person Filing:

Edgar Filing: LYNX THERAPEUTICS INC - Form SC 13G

This Schedule 13G is being filed with respect to shares of Common Stock of the Issuer which are beneficially owned by Joseph Edelman. See Item 4 below.

Item 2(b). Address of Principal Business Office, or, if None, Residence:

c/o First New York Securities, LLC
850 Third Avenue, 8th Floor
New York, NY 10022

Item 2(c). Citizenship:

Mr. Edelman is a United States Citizen.

Item 2(d). Title of Class of Securities:

Common Stock, \$0.01 par value per share

Item 2(e). CUSIP NUMBER:

551812308

Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person Filing is a:

- (a) Broker or dealer registered under Section 15 of the Act.
- (b) Bank as defined in Section 3(a)(6) of the Act.
- (c) Insurance Company as defined in Section 3(a)(19) of the Act.
- (d) Investment Company registered under Section 8 of the Investment Company Act.
- (e) Investment Adviser in accordance with Sec. 240.13d-1(b)(1)(ii)(E).
- (f) Employee Benefit Plan or Endowment Fund in accordance with Sec. 240.13d-1(b)(1)(ii)(F).
- (g) Parent holding company, in accordance with Sec. 240.13d-1(b)(ii)(G).
- (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act.
- (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940.
- (j) Group, in accordance with Sec. 240.13d-1(b)(1)(ii)(J). If this statement is filed pursuant to Sec. 240.13d-1(C), check this box

CUSIP No. 551812308

13G

Page 4 of 5

Item 4. Ownership.

Edgar Filing: LYNX THERAPEUTICS INC - Form SC 13G

(a) Amount beneficially owned:

2,700,000 (comprised of 1,936,000 shares of Common Stock, par value \$0.01 per share and warrants to purchase 760,000 shares of Common Stock, par value \$0.01 per share held by Perceptive Life Sciences Master Fund Ltd., a Cayman Island company, the investment manager of which is Perceptive Advisors LLC, a Delaware limited liability company, of which Mr. Edelman is the managing member and 4,000 shares of Common Stock, par value \$0.01 per share held by Mr. Edelman through his trading account with First New York Securities, LLC).

(b) Percent of class:

9.26%

(c) Number of shares as to which such person has:

- (i) Sole power to vote or to direct the vote 2,700,000
- (ii) Shared power to vote or to direct the vote 0
- (iii) Sole power to dispose or to direct the disposition of 2,700,000
- (iv) Shared power to dispose or to direct the disposition of 0

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the Beneficial owner of more than five percent of the class of securities, check the following [].

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Reported on by the Parent Holding Company.

Not applicable.

Item 8. Identification and Classification of members of the Group.

Not applicable.

Item 9. Notice of Dissolution of Group.

Not applicable.

CUSIP No. 551812308

13G

Page 5 of 5

Item 10. Certification.

Edgar Filing: LYNX THERAPEUTICS INC - Form SC 13G

By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true and correct.

April 29, 2002

(Date)

/s/ Joseph Edelman

(Signature)

Joseph Edelman

(Name/Title)